Global Renal Drugs Market, By Drugs (Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy) – Industry Trends and Forecast to 2029.
Renal Drugs Market Analysis and Size
The global renal drugs market is expected to witness significant growth during the forecast period. Rising prevalence of chronic kidney diseases worldwide and the growing markets are the factors responsible for expanding this market. The growth of global renal drugs market is enhanced by the growing cases of kidney diseases and the rise in R&D activities conducted by many pharmaceutical companies. COVID-19 also had a major impact on the market growth.
Data Bridge Market Research analyses a growth rate in the global renal drugs market in the forecast period 2022-2029. The expected CAGR of global renal drugs market is tend to be around 5% in the mentioned forecast period. The market was valued at USD 15 billion in 2021, and it would grow upto USD 22.16 billion by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
Market Definition
Renal drugs are a great boon to patients in controlling several problems that cause conditions and complications during kidney diseases. It helps treat many other symptoms of kidney failure such as anemia, loss of appetite, and feeling out of breath. But, in general, kidney transplantation is considered to be the most effective treatment for advanced kidney disease.
Renal Drugs Market Scope and Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2022 to 2029
|
|
Base Year
|
2021
|
|
Historic Years
|
2020 (Customizable to 2014 - 2019)
|
|
Quantitative Units
|
Revenue in USD Million, Volumes in Units, Pricing in USD
|
|
Segments Covered
|
Drugs (Antihypertensive Agents, Erythropoiesis-Stimulating Agents, Diuretics, ACE Inhibitors, Antidiabetic Agents, Others), Route of Administration (Oral, Parenteral, Others), End-Users (Hospitals, Homecare, Specialty Clinics, Others), Distribution Channel (Hospital Pharmacy, Online Pharmacy, Retail Pharmacy)
|
|
Countries Covered
|
U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America
|
|
Market Players Covered
|
Pfizer Inc (U.S.), AstraZeneca (U.K.), Bristol-Myers Squibb Company (U.S.), AbbVie.Inc (Ireland), Dr. Reddy's Laboratories Ltd (India), Endo International plc (Ireland), Teva Pharmaceutical Industries Ltd (Israel), Sun Pharmaceutical Industries Ltd (India), Mylan N.V. (U.S.), Novartis AG (Switzerland), Lupin (India), Cipla Inc (India), Aurobindo Pharma (India), Fresenius SE & Co. KGaA (Germany), Sanofi (France), Takeda Pharmaceutical Company Limited (Japan), F. Hoffmann-La Roche Ltd (Switzerland), Abbott (U.S.)
|
|
Market Opportunities
|
|
Global Renal Drugs Market Dynamics
Drivers
- Increased Incidence of Kidney Diseases
The rising prevalence of chronic kidney disease worldwide is majorly responsible for boosting the growth of the global renal drugs market. According to the National Kidney Foundation reports, approximately 10% of the global population is affected by chronic kidney disease (CKD). Thus, it boosts the market growth.
- Rising Demand for Oral Drugs
Oral drugs is expected to boost the market growth. The segment is expected to accelerate the global market as most products are available in capsule and tablet form and it is a very feasible route of administration.
Opportunities
- Increased Drug Approvals
The increased approval from the FDA and other authorities for the renal drugs creates many opportunities for the market's growth. For instance, Marck Sharp and Dohme Corp. got an approval from FDA for KEYTRUDA to treat patients suffering from renal cell carcinoma. Thus, all these factors enhance the market expansion.
- Increasing Demand for Retail Pharmacies
The rise in the number of renal drugs delivered through retail pharmacies and the surge in the number of retail pharmacies in developed countries create opportunities for the market growth. In addition to this, patients prefer retail pharmacies for purchasing drugs, as these are easily accessible.
Restraints/Challenges
- Side Effects of Renal Drugs
The side effects associated with these renal drugs could curb the growth of the global renal drugs market over a forecast period. Effects such as loss of appetite, fever, rashes, can hamper the market growth.
- High Cost
The huge expenditure associated with these agents surely hamper the market growth.
This global renal drugs market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global renal drugs market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.
COVID-19 Impact on Global Renal Drugs Market
Considering the present scenario, COVID-19 has left an unprecedented global public health crisis that has impacted practically every business. Its long-term repercussions are expected to influence industry growth during the forecast period. Transition of healthcare infrastructure toward managing COVID-19 has led to drug launch cancellations and delays in clinical trials.
Pericarditis witnessed to be widespread during the pandemic but was rarely seen in the post-acute period, on the other hand minor pericardial effusions seem to be very common during the COVID-19 post-acute period. Additionally, post-COVID pericarditis is found to be linked to continuing inflammation. Thus, overall, COVID-19 had a major impact on the global renal drugs market.
Global Renal Drugs Market Scope
The global renal drugs market is segmented on the basis of drugs, route of administration, distribution channel and end-user. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.
Drugs
- Antihypertensive Agents
- Erythropoiesis-Stimulating Agents
- Diuretics
- ACE Inhibitors
- Antidiabetic Agents
- Others
Route of Administration
- Oral
- Parenteral
- Others
End User
- Hospitals
- Homecare
- Specialty Clinics
- Others
Distribution Channel
- Hospital Pharmacy
- Online Pharmacy
- Retail Pharmacy
Renal Drugs Market Regional Analysis/Insights
The global renal drugs market is analysed and market size insights and trends are provided by drugs, route of administration, distribution channel and end-user as referenced above.
The major countries covered in the global renal drugs market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.
Asia-Pacific has been witnessing a highest growth for global renal drugs market throughout the forecasted period due to increased smoking, hypertension & diabetic population, and presence of key manufacture of the product.
North America dominates the market due to increased smoking, hypertension & diabetic population, and presence of key manufacture of the product.
The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.
Competitive Landscape and Global Renal Drugs Market Share Analysis
The global renal drugs market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global renal drugs market.
Key players operating in the global renal drugs market include:
- Pfizer Inc (U.S.)
- AstraZeneca (U.K.)
- Bristol-Myers Squibb Company (U.S.)
- Allergan,Inc (Ireland)
- Dr. Reddy's Laboratories Ltd (India)
- Endo International plc (Ireland)
- Teva Pharmaceutical Industries Ltd (Israel)
- Sun Pharmaceutical Industries Ltd (India)
- Mylan N.V. (U.S.)
- Novartis AG (Switzerland)
- Lupin (India)
- Cipla Inc (India)
- Aurobindo Pharma (India)
- Fresenius SE & Co. KGaA (Germany)
- Sanofi (France)
- Takeda Pharmaceutical Company Limited (Japan)
- F. Hoffmann-La Roche Ltd (Switzerland)
- Abbott (U.S.)
SKU-